Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 292,780,416
  • Shares Outstanding, K 3,101,816
  • Annual Sales, $ 54,073 M
  • Annual Income, $ 7,035 M
  • EBIT $ 12,801 M
  • EBITDA $ 19,489 M
  • 60-Month Beta 0.34
  • Price/Sales 4.83
  • Price/Cash Flow 14.99
  • Price/Book 6.37

Options Overview Details

View History
  • Implied Volatility 29.92% (-0.83%)
  • Historical Volatility 24.68%
  • IV Percentile 88%
  • IV Rank 37.40%
  • IV High 47.30% on 04/08/25
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 30) 5.61 (6.24%)
  • Put/Call Vol Ratio 0.65
  • Today's Volume 3,034
  • Volume Avg (30-Day) 4,241
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 78,712
  • Open Int (30-Day) 126,114
  • Expected Range 84.33 to 95.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.09
  • Number of Estimates 5
  • High Estimate 1.18
  • Low Estimate 1.03
  • Prior Year 1.05
  • Growth Rate Est. (year over year) +3.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.17 +0.86%
on 01/20/26
96.51 -6.81%
on 01/07/26
-1.42 (-1.55%)
since 12/19/25
3-Month
80.48 +11.75%
on 11/04/25
96.51 -6.81%
on 01/07/26
+6.07 (+7.24%)
since 10/20/25
52-Week
61.24 +46.86%
on 04/09/25
96.51 -6.81%
on 01/07/26
+23.34 (+35.05%)
since 01/17/25

Most Recent Stories

More News
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 33.52 (-1.18%)
AZN : 89.94 (-4.71%)
OZEM : 35.72 (-1.33%)
NVO : 60.68 (-2.65%)
LLY : 1,041.29 (+0.28%)
REGN : 733.78 (+0.10%)
AMGN : 331.00 (+0.18%)
PFE : 25.52 (-0.51%)
Looking to ‘Sell America’ Amid Fed Drama? Here’s 1 ETF to Buy.

'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.

BLK : 1,110.05 (-4.57%)
BABA : 162.39 (-1.82%)
DXY00 : 98.629 (-0.01%)
SIH26 : 94.865 (+0.24%)
GCG26 : 4,861.7 (+2.01%)
NVS : 143.58 (-0.53%)
RHHBY : 54.4300 (+0.33%)
HSBC : 82.50 (-0.04%)
TSM : 327.16 (-4.45%)
ASML : 1,326.07 (-2.39%)
$DXY : 98.63 (-0.01%)
AZN : 89.94 (-4.71%)
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

AZN : 89.94 (-4.71%)
Alibaba Was the Market’s Favorite Chinese AI Stock in 2025: What’s BABA’s 2026 Forecast?

Alibaba established itself as a preeminent AI play in China this year, which helped support its rally. The 2026 outlook also looks reasonably good after the recent fall.

BABA : 162.39 (-1.82%)
AAPL : 246.70 (-3.46%)
AZN : 89.94 (-4.71%)
BMWKY : 33.5600 (-2.33%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s ENHERTU with the latest based on DESTINY-Breast05 Phase III trial results

AZN : 89.94 (-4.71%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 89.94 (-4.71%)
PPCB : 0.2988 (-4.69%)
RHHBY : 54.4300 (+0.33%)
BMY : 54.22 (-1.88%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with...

AZN : 89.94 (-4.71%)
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers ...

AZN : 89.94 (-4.71%)
IonQ Wants to Bring Quantum Computing to Medicine. Should You Buy IONQ Stock Here?

With IonQ bringing quantum computing into healthcare, is now the time for investors to start paying attention to this stock?

NVDA : 178.07 (-4.38%)
AZN : 89.94 (-4.71%)
$SPX : 6,796.86 (-2.06%)
IONQ : 50.66 (-0.28%)
AMZN : 231.00 (-3.40%)
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled...

AZN : 89.94 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 92.93
2nd Resistance Point 92.02
1st Resistance Point 90.98
Last Price 89.94
1st Support Level 89.04
2nd Support Level 88.13
3rd Support Level 87.09

See More

52-Week High 96.51
Last Price 89.94
Fibonacci 61.8% 83.04
Fibonacci 50% 78.88
Fibonacci 38.2% 74.71
52-Week Low 61.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar